Overview A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors Status: Not yet recruiting Trial end date: 2023-01-01 Target enrollment: Participant gender: Summary A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors Phase: Phase 1 Details Lead Sponsor: I-Mab Biopharma Co. Ltd.